---
title: "Fulgent Presents Updated Phase 2 FID-007 + Cetuximab Data at ASCO Showing 61.9% ORR"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/288405208.md"
description: "Fulgent Genetics presented updated Phase 2 data at ASCO for FID-007 combined with cetuximab in recurrent/metastatic head and neck squamous cell carcinoma. The regimen showed a 61.9% objective response rate, 63.4% one-year overall survival, and manageable safety. Fulgent plans to initiate a Phase 3 study based on these results."
datetime: "2026-06-02T10:13:00.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/288405208.md)
  - [en](https://longbridge.com/en/news/288405208.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/288405208.md)
generator: "portal-rs"
---

# Fulgent Presents Updated Phase 2 FID-007 + Cetuximab Data at ASCO Showing 61.9% ORR

**Fulgent presented updated Phase 2 data showing a 61.9% objective response rate for FID-007 combined with cetuximab in R/M HNSCC.**

**Key Highlights:**

-   Presented updated preliminary Phase 2 (NCT06332092) data in ASCO Rapid Oral session for FID-007 + cetuximab.
-   As of Apr 16, 2026 cutoff: objective response rate 61.9%, median PFS 6.7 months, median DOR 7.4 months.
-   One-year overall survival reported at 63.4% and activity seen in HPV‑related and unrelated HNSCC.
-   Study evaluated two dosing regimens and assessed PK, safety and tolerability; safety described as manageable.
-   Company plans a Phase 3 study; updated presentation slides posted on investor site after the June 1 presentation.

Original SEC Filing: Fulgent Genetics, Inc. \[ FLGT \] - 8-K - Jun. 01, 2026

**Disclaimer**

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

### Related Stocks

- [FLGT.US](https://longbridge.com/en/quote/FLGT.US.md)

## Related News & Research

- [Fulgent Genetics Q2 revenue rises 20% sequentially, sees billing system transition delay](https://longbridge.com/en/news/294410077.md)
- ["The Market Gets It Wrong," Says Investor About CoreWeave Stock](https://longbridge.com/en/news/301869526.md)
- [Intuit vs. Oracle: One Software Stock Faces Competition, the Other Is a Risk Worth Taking, Says Top Investor](https://longbridge.com/en/news/301861616.md)
- [CoreWeave Chief Revenue Officer Jonathan Jones Reports Disposal of $2.94 Million in Common Shares](https://longbridge.com/en/news/301896236.md)
- [ASML Makes a Massive Move to Reward Shareholders](https://longbridge.com/en/news/301870415.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**